RBC Capital lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $172 from $182 and keeps an Outperform rating on the shares after its Q1 results. The company saw a “pressured quarter” beyond seasonality with several transient and one-time effects, though its FY25 revenue guidance remains the same, implying some degree of confidence amidst the murky backdrop, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals price target lowered to $147 from $176 at Piper Sandler
- Jazz Pharmaceuticals price target lowered to $155 from $167 at Baird
- Jazz Pharmaceuticals price target raised to $216 from $213 at BofA
- Jazz Pharmaceuticals price target lowered to $166 from $183 at Morgan Stanley
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts